Affiliation:
1. Department of Orthopedics The First Affiliated Hospital of Soochow University 188 Shizi Road Suzhou Jiangsu 215006 China
2. Department of Orthopedics, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui 230022 China
3. Institute for Advanced Materials, School of Materials Science and Engineering Jiangsu University Zhenjiang Jiangsu 212013 China
4. National Center for Translational Medicine (Shanghai) SHU Branch Shanghai University Shanghai 200240 China
Abstract
AbstractIntracellular oligonucleotide delivery possesses unparalleled potential for precise regulation of pathogenic gene expression and alteration of cell destiny. However, limited by its feeble resistance against humoral environment, hindered intracellular transportation, and lysosomal phagocytosis, oligonucleotide therapy remains a formidable challenge. The discovery of cationic peptides has provided innovative insights for the effective delivery of oligonucleotides, yet the stable, efficient, and convenient assembly of peptides and oligonucleotides remains an elusive goal, referred to as the “Holy Grail” challenge in the field. Addressing this challenge, it has pioneered the development of a straightforward and highly efficient engineering carrier‐free covalent peptide‐oligonucleotide nano‐conjugates (PONs) through a mild click reaction. Notably, this PONs can realize self‐assemble into nanoparticles under amphiphilic electrostatic interactions, which exhibits significant RNase resistance and surprisingly effective intracellular oligonucleotide delivery as well as lysosomal escape. Based on this strategy, a PONs named CPP‐(DOPA)6‐miRNA‐223 is synthesized, which demonstrates rapid and effective cellular uptake, swift lysosomal escape in macrophage, remarkable accumulation in inflammatory regions and excellent therapeutic effect in an inflammatory arthritis model. Therefore, this work may provide a breakthrough for the clinical application of all oligonucleotide delivery therapies and expanding the applications in gene therapy.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Jiangsu Province
Priority Academic Program Development of Jiangsu Higher Education Institutions
National Postdoctoral Program for Innovative Talents
China Postdoctoral Science Foundation